Minneapolis, MN, June 08, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company
developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP)
marketplace, today announced the launch of a new corporate website, www.biosigtech.com.
The new website has a fresh look and easy navigation to get shareholders and visitors to what they need quickly. The site
provides easy to understand information on electrophysiology, the current problem, our solution, as well as links to recent papers
covering our technology in academic literature.
"BioSig’s revamped website will allow us to broaden our audience and more effectively communicate the material advancements that
we are making within the rapidly emerging medical technology industry,” stated Mr. Ken Londoner, Chief Executive Officer, Chairman
& Founder, BioSig Technologies, Inc. “In addition to making strides toward commercialization, we’ve been featured in prestigious
outlets such as The Journal of the American College of Cardiology: Clinical Electrophysiology (JACC:CEP) and the
Journal of Innovations in Cardiac Rhythm Management. We believe that the new site will allow us to better serve as an information
portal to potential shareholders as well as those interested in researching updates to the electrophysiology (EP) marketplace.”
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4 billion
electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors,
Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed
to address an unmet need in a large and growing market.
The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists
in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main
goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA
510(k) clearance and CE Mark for the PURE EP System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web
site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Investor Relations: Lora Mikolaitis BioSig Technologies, Inc. lmikolaitis@biosigtech.com 310.948.7200
